[Treatment of rheumatoid and psoriatic arthritis--review of leflunomide].
نویسندگان
چکیده
161 1Klinika za reumatske bolesti i rehabilitaciju Referentni centar MZSS RH za reumatoidni artritis Klinički bolnički centar Zagreb Kišpatićeva 12 10000 Zagreb 2Zavod za kliničku imunologiju i reumatologiju Klinika za unutarnje bolesti Klinički bolnički centar Zagreb Kišpatićeva 12 10000 Zagreb 3Odjel za reumatologiju i kliničku imunologiju Klinika za internu medicinu Klinički bolnički centar Rijeka Krešimirova 42 51000 Rijeka 4Klinika za reumatologiju, fi zikalnu medicinu i rehabilitaciju Referentni centar MZSS RH za spondiloartropatije Klinička bolnica “Sestre milosrdnice” Vinogradska 29 10000 Zagreb 5Odsjek za kliničku imunologiju i reumatologiju Klinika za unutarnje bolesti Klinički bolnički centar Split Spinčićeva 1 21000 Split SPONZORIRANO PRIOPĆENJE SPONSORED COMMUNICATION
منابع مشابه
Non-healing tongue ulcer in a rheumatoid arthritis patient medicated with leflunomide. An adverse drug event?
Leflunomide is a member of the disease modifying anti-rheumatic drugs group used as a treatment modality in active rheumatoid and psoriatic arthritis. "Oral ulcers" are reported in 3-5% of leflunomide medicated rheumatoid arthritis patients with adverse events, but they are not described in detail in the literature. We present a case of an ulcer in the tongue of a rheumatoid arthritis patient m...
متن کاملReappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis
Leflunomide is a disease-modifying antirheumatic drug (DMARD) that has been in routine clinical use for the treatment of rheumatoid arthritis (RA) and psoriatic arthritis for a decade. In RA, clinical trials of up to two years' duration showed that leflunomide monotherapy was equivalent to methotrexate in clinical and radiographic disease outcomes (tender and swollen joint counts, physician and...
متن کاملComparing bone mineral density in rheumatoid arthritis and psoriatic arthritis
Background: Changes in patients’ bone mineral density (BMD) is one of the problems in patients with rheumatoid arthritis, which can be due to the use of corticosteroid drugs to reduce patients' symptoms or due to the aging process in patients. In this study, we decided to compare BMD in patients with psoriatic arthritis and rheumatoid arthritis. Methods: This study as a cross-sectional descrip...
متن کاملDisease-modifying antirheumatic drug therapy for psoriatic arthritis.
As erosive and deforming arthritis is present in 40% of patients with psoriatic arthritis (PsA), early and aggressive treatment with disease-modifying antirheumatic drugs (DMARDs) may be as effective in controlling the progression of the disease as it is for rheumatoid arthritis (RA). Methotrexate (MTX), sulfasalazine (SSZ), and cyclosporine (CsA) are the most widely used DMARDs in the treatmen...
متن کاملPotential role of apremilast
2014 Psoriatic arthritis is a chronic inflammatory disease of the joints that occurs in patients with psoriasis. Nonbiologic disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate and leflunomide, and biologic DMARDs such as TNF antagonists and ustekinumab, have been used in the treatment of this disease. Apremilast is a novel therapy that inhibits phosphodiesterase 4 and increase...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Reumatizam
دوره 57 2 شماره
صفحات -
تاریخ انتشار 2010